Fig 1.
CONSORT flow chart of the study.
Table 1.
Population characteristics at inclusion, and after 12 years.
Fig 2.
Kaplan-Meier graph illustrating cardiovascular mortality during a follow-up period of 12 years of those supplemented with selenium and coenzyme Q10 versus placebo for four years on top of regular pharmaceutical treatment.
Table 2.
Cox proportional hazard regression analysis evaluating risk of cardiovascular mortality by supplementation of selenium and coenzyme Q10 combined in a multivariate model after 12 years of follow-up after 4 years of intervention to an elderly community population.
Fig 3.
Kaplan-Meier graph illustrating cardiovascular mortality in participants with ischemic heart disease during a follow-up period of 12 years of those supplemented with selenium and coenzyme Q10 versus placebo for four years on top of regular pharmaceutical treatment.
Fig 4.
Kaplan-Meier graph illustrating cardiovascular mortality in participants with diabetes during a follow-up period of 12 years of those supplemented with selenium and coenzyme Q10 versus placebo for four years on top of regular pharmaceutical treatment.
Fig 5.
Kaplan-Meier graph illustrating cardiovascular mortality in participants with hypertension during a follow-up period of 12 years of those supplemented with selenium and coenzyme Q10 versus placebo for four years on top of regular pharmaceutical treatment.
Fig 6.
Kaplan-Meier graph illustrating cardiovascular mortality in participants with NYHA functional class III during a follow-up period of 12 years of those supplemented with selenium and coenzyme Q10 versus placebo for four years on top of regular pharmaceutical treatment.
Table 3.
Model testing the effect of intervention after 12 years on risk for cardiovascular mortality in different groups.
Table 4.
Difference in cardiovascular mortality within 5, 10 and 12 years after intervention of selenium and coenzyme Q10 combined or placebo for four years.
Table 5.
Mortality rate after 5 years, 10 years and 12 years in the active treatment group compared to the placebo group, and to official mortality statistics.